Table 1 Summary of the included SRs of ECMO treatment
First author, publication year | Disease | Design of primary studies | No. of primary studies | No. of included RCTs | No. of participants | Outcome | Conclusion |
|---|---|---|---|---|---|---|---|
Munshi 2019 [31] | ARDS | RCT, observational study | 5 | 2 | 899 | 60-Day mortality, treatment failure, mortality at longest available follow-up | Probably beneficial |
Shrestha 2022 [38] | Dependent ARDS | RCT, retrospective study, prospective observational study, cohort study | 12 | 2 | 1208 | 30-Day mortality, 90-day mortality, in-hospital mortality, ICU mortality, length of hospital stays, average ICU length of stay | Inconclusive |
Tillmann 2017 [27] | Severe ARDS | RCT, cohort study | 26 | 1 | 1674 | Survival, adverse events | Inconclusive |
Mendes Pedro Vitale, 2019 [30] | Severe ARDS | RCT | 2 | 2 | 429 | Mortality, treatment failure, need for renal replacement therapy, ICU lengths of stay, hospital lengths of stay | Probably beneficial |
Alain Combes, 2020 [32] | Severe ARDS | RCT | 2 | 2 | 429 | 90-Day mortality, 90-day treatment failure, 28-day mortality, 60-day mortality, ICU-free days, hospital-free days, ventilation-free days, vasopressor-free days, RRT-free days, neurological failure-free days | Beneficial |
Zhu, 2021 [36] | Severe ARDS | RCT, retrospective or prospective cohort study | 7 | 2 | 867 | 90-Day mortality, 30-day mortality, 60-day mortality, hospital mortality, mortality at the longest duration of follow-up, device-related adverse events (pneumothorax, massive bleeding, intracranial bleeding, cardiac arrest, massive stroke and death due to MV or ECMO) | Beneficial |
Munshi, 2014 [24] | ARF | RCT, observational study | 10 | 4 | 1248 | In-hospital mortality, ICU length of stay, adverse events (bleeding, barotrauma, and sepsis) | Inconclusive |
Mitchell, 2010 [22] | ARF due to H1N1 influenza pandemic | RCT, cohort study | 6 | 3 | 827 | Mortality | Inconclusive |
Alberto Zangrillo, 2013 [23] | ALI due to H1N1 influenza infection | Observational study | 8 | 0 | 1357 | Mortality | Beneficial |
Alshamsi Fayez, 2020 [34] | ALF or ACLF | RCT | 25 | 25 | 1796 | Mortality, hepatic encephalopathy outcome, adverse events (hypotension, bleeding, thrombocytopenia, line infections) | Probably beneficial |
Ouweneel Dagmar, 2016 [26] | Cardiac arrest | Cohort study | 10 | 0 | 3127 | 30-Day survival rate, 30-day favorable neurological outcome | Beneficial |
Beyea, 2018 [28] | Cardiac arrest | Case series, cohort study | 75 | 0 | 5570 | Neurologic status at hospital discharge, survival | Inconclusive |
Twohig, 2019 [29] | Cardiac arrest | Retrospective or prospective observational study | 9 | 0 | 26,030 | Survival at hospital discharge or 30 days, neurological function | Probably beneficial |
Miraglia, 2020 [33] | Cardiac arrest | Cohort study | 6 | 0 | 1108 | 30-Day and long-term favorable neurological outcome, 30-day and long-term survival | Probably beneficial |
Miraglia, 2020 [35] | Cardiac arrest | Cohort study, case–control study | 6 | 0 | 1750 | Long-term neurological intact survival | Probably beneficial |
Scquizzato, 2022 [37] | Cardiac arrest | RCT, observational study | 6 | 2 | 1177 | Survival with favorable neurological outcome at the longest follow-up available, survival at the longest follow-up available/hospital discharge/30 days, rate of neurological impairments | Beneficial |
Ahn Chiwon, 2016 [25] | Cardiac arrest of cardiac origin | Retrospective or prospective cohort study | 11 | 0 | 38,160 | Survival, overall neurologic outcome | Probably beneficial |